Median progression-free survival was @ months ( @ % CI @-@ ) in the cetuximab group and @ months ( @-@ ) in the bevacizumab group ( hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p = @ ) ; however , median overall survival was @ months ( @ % CI @-@ ) in the cetuximab group compared with @ months ( @-@ ) in the bevacizumab group ( HR @ , @ % CI @-@ ; p = @ ) .